Summary
Global Markets Direct’s, ‘Brain Ischemia - Pipeline Review, H1 2016’, provides an overview of the Brain Ischemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Brain Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Brain Ischemia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Brain Ischemia
- The report reviews pipeline therapeutics for Brain Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Brain Ischemia therapeutics and enlists all their major and minor projects
- The report assesses Brain Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Brain Ischemia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Brain Ischemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
CohBar, Inc.
Lixte Biotechnology Holdings, Inc.
NeuroNascent, Inc.
NeurOp, Inc
Prolong Pharmaceuticals, LLC
Spectrum Pharmaceuticals, Inc.
Sylentis S.A.U.
Vect-Horus S.A.S.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Brain Ischemia Overview 7
Therapeutics Development 8
Pipeline Products for Brain Ischemia - Overview 8
Pipeline Products for Brain Ischemia - Comparative Analysis 9
Brain Ischemia - Therapeutics under Development by Companies 10
Brain Ischemia - Therapeutics under Investigation by Universities/Institutes 11
Brain Ischemia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Brain Ischemia - Products under Development by Companies 14
Brain Ischemia - Products under Investigation by Universities/Institutes 15
Brain Ischemia - Companies Involved in Therapeutics Development 16
CohBar, Inc. 16
Lixte Biotechnology Holdings, Inc. 17
NeuroNascent, Inc. 18
NeurOp, Inc 19
Prolong Pharmaceuticals, LLC 20
Spectrum Pharmaceuticals, Inc. 21
Sylentis S.A.U. 22
Vect-Horus S.A.S. 23
Brain Ischemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AB-002 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ADA-409 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CN-105 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Humanin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
LAU-0901 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
LB-100 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NP-10679 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
phycocyanobilin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Sanguinate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules for Brain Ischemia - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SPI-1620 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Stem Cell Therapy for Ischemia - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Synthetic Peptide for Central Nervous System Disorders - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
VHN-439 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Brain Ischemia - Recent Pipeline Updates 57
Brain Ischemia - Dormant Projects 60
Brain Ischemia - Discontinued Products 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64
List of Tables
Number of Products under Development for Brain Ischemia, H1 2016 8
Number of Products under Development for Brain Ischemia - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Brain Ischemia - Pipeline by CohBar, Inc., H1 2016 16
Brain Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 17
Brain Ischemia - Pipeline by NeuroNascent, Inc., H1 2016 18
Brain Ischemia - Pipeline by NeurOp, Inc, H1 2016 19
Brain Ischemia - Pipeline by Prolong Pharmaceuticals, LLC, H1 2016 20
Brain Ischemia - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 21
Brain Ischemia - Pipeline by Sylentis S.A.U., H1 2016 22
Brain Ischemia - Pipeline by Vect-Horus S.A.S., H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Brain Ischemia Therapeutics - Recent Pipeline Updates, H1 2016 57
Brain Ischemia - Dormant Projects, H1 2016 60
Brain Ischemia - Dormant Projects (Contd..1), H1 2016 61
Brain Ischemia - Discontinued Products, H1 2016 62
List of Figures
Number of Products under Development for Brain Ischemia, H1 2016 8
Number of Products under Development for Brain Ischemia - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Targets, H1 2016 25
Number of Products by Stage and Targets, H1 2016 25
Number of Products by Mechanism of Actions, H1 2016 27
Number of Products by Stage and Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Top 10 Molecule Types, H1 2016 31
